Drug intelligence / Profile preview

WTX-607 (WaveBreak Therapeutics)

Development stage: Unknown
Lead developer: WaveBreak Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

WTX-607 (formerly WTX-A) is an orally bioavailable, brain-penetrant small molecule inhibitor of alpha-synuclein oligomer generation, originally developed by Wren Therapeutics (now WaveBreak) in collaboration with Eisai. WTX-607 is designed to target the key molecular mechanisms responsible for the generation of toxic alpha-synuclein oligomers, specifically inhibiting both primary (lipid-induced) nucleation and secondary nucleation processes. By preventing the formation of these toxic oligomeric intermediates, WTX-607 aims to halt the progression of neurodegeneration in synucleinopathies, including Parkinson's disease, Lewy body dementia, and multiple system atrophy.

Other names: small molecule alpha-synuclein oligomer inhibitor

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on WTX-607 (WaveBreak Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WTX-607 (WaveBreak Therapeutics).